Alnylam Pharmaceuticals, Inc. announced the completion of the rolling submission of a New Drug Application (NDA) to the FDA for lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase… read more.
Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs, drug supply chain, and business operations The Company announced measures it… read more.
A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro (sucroferric oxyhydroxide chewable tablets), from Fresenius Medical, achieved target… read more.
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped… read more.
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped… read more.
OPKO Health reported interim results from an ongoing Phase IV clinical trial comparing Rayaldee with three common treatment regimens for secondary hyperparathyroidism (SHPT) in adult patients with stage… read more.
Oncology Venture has had a meeting with the FDA to discuss a potential path to approval for dovitinib used to treat Renal Cell Carcinoma (RCC) (kidney cancer), the… read more.
Researchers find that several genetic disorders, including MUC1 kidney disease, may share a novel molecular mechanism — and identify a promising therapeutic lead. Misfolded MUC1-fs protein (green) builds up in the kidneys of a mouse model of MUC1 kidney disease.
A new study from St. Michael’s Hospital in Toronto, Canada shed lights on how a class of medications that help regulate blood sugar for patients with Type 2… read more.
People with high blood pressure who take all their anti-hypertensive medication in one go at bedtime have better controlled blood pressure and a significantly lower risk of death… read more.
These kidney macrophages reprogram to a developmental state after kidney injury, similar to those in newborn mice.
by Bruce Sylvester: Researchers have identified an across-the-board cardiovascular benefit for patients treated with a diabetes drug, liraglutide, with decreases reported in overall risk of heart attack, stroke,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
